New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
Executive Summary
The addressable patient population in the US could increase by 4.5m if new trial is successful.
| Table |
|---|
Advertisement
Related Content
Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Medicines Company Gets Aggressive With Inclisiran Phase III Plans
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
Topics
- Subjects
- Clinical Trials
- Research & Development
- Therapy Areas
- Cardiovascular
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124917
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC124917
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.